(Q51987714)

19 April 2018

title

Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. (English)

1 reference

19 April 2018

1 reference

Yamakita T

1

1 reference

19 April 2018

Ishii T

2

1 reference

19 April 2018

Mori T

3

1 reference

19 April 2018

Yoshioka K

4

1 reference

19 April 2018

Sato T

5

1 reference

19 April 2018

Tanaka S

6

1 reference

19 April 2018

Kurimasa H

7

1 reference

19 April 2018

Fujita K

8

1 reference

19 April 2018

Fujii S

9

1 reference

19 April 2018

publication date

1 December 1998

1 reference

19 April 2018

Diabetes Research and Clinical Practice

published in

1 reference

19 April 2018

volume

42

1 reference

19 April 2018

issue

3

1 reference

19 April 2018

page(s)

205-208

1 reference

19 April 2018

The Prader-Willi syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Prader-Willi syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Hyperlipidemia, insulin-dependent diabetes mellitus, and rapidly progressive diabetic retinopathy and nephropathy in Prader-Willi syndrome with del(15)(q11.2q13)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Prader-Willi syndrome. A resumé of 32 cases including an instance of affected first cousins, one of whom is of normal stature and intelligence

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Prader-Willi Syndrome after age 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

A reduced number of insulin receptors in patients with Prader-Willi syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Effects of mazindol in two patients with Prader-Willi syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

Anorectic drugs: use in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2898%2900111-9

7 January 2021

10.1016/S0168-8227(98)00111-9

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018